These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 31390167)
1. Evolution of mitral regurgitation in patients with heart failure referred to a tertiary heart failure clinic. de Groot-de Laat LE; Huizer J; Lenzen M; Spitzer E; Ren B; Geleijnse ML; Caliskan K ESC Heart Fail; 2019 Oct; 6(5):936-943. PubMed ID: 31390167 [TBL] [Abstract][Full Text] [Related]
2. Neurohormonal and Transcatheter Repair Strategies for Proportionate and Disproportionate Functional Mitral Regurgitation in Heart Failure. Packer M; Grayburn PA JACC Heart Fail; 2019 Jun; 7(6):518-521. PubMed ID: 31078484 [No Abstract] [Full Text] [Related]
3. Percutaneous repair of mitral valve regurgitation in patients with severe heart failure: comparison with optimal medical treatment. Geis N; Raake P; Lewening M; Mereles D; Chorianopoulos E; Frankenstein L; Katus HA; Bekeredjian R; Pleger ST Acta Cardiol; 2018 Aug; 73(4):378-386. PubMed ID: 29161956 [TBL] [Abstract][Full Text] [Related]
4. Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy. Penn J; Goldenberg I; McNitt S; Polonsky B; Ruwald MH; Zareba W; Moss AJ; Alexis JD J Card Fail; 2015 Jul; 21(7):541-7. PubMed ID: 25800548 [TBL] [Abstract][Full Text] [Related]
5. Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection Fraction. Nasser R; Van Assche L; Vorlat A; Vermeulen T; Van Craenenbroeck E; Conraads V; Van der Meiren V; Shivalkar B; Van Herck P; Claeys MJ JACC Heart Fail; 2017 Sep; 5(9):652-659. PubMed ID: 28859754 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
7. Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy. Vijayalakshmi IB; Yavagal ST; Prabhudev N Echocardiography; 2005 Apr; 22(4):289-95. PubMed ID: 15839983 [TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy in the treatment of mitral regurgitation: a systematic review. Strauss CE; Duval S; Pastorius D; Harris KM J Heart Valve Dis; 2012 May; 21(3):275-85. PubMed ID: 22808826 [TBL] [Abstract][Full Text] [Related]
9. Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Nielsen JC Eur Heart J Cardiovasc Pharmacother; 2015 Jul; 1(3):182-8. PubMed ID: 27533993 [TBL] [Abstract][Full Text] [Related]
10. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. Bristow MR; Saxon LA; Feldman AM; Mei C; Anderson SA; DeMets DL JACC Heart Fail; 2016 Jul; 4(7):521-535. PubMed ID: 27289408 [TBL] [Abstract][Full Text] [Related]
11. Effective regurgitant orifice area of rheumatic mitral insufficiency: response to angiotensin converting enzyme inhibitor treatment. Tunaoğlu FS; Olguntürk R; Kula S; Oğuz D Anadolu Kardiyol Derg; 2004 Mar; 4(1):3-7. PubMed ID: 15033608 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors in pediatric patients with mitral valve regurgitation-case-control study and review of the literature. Knirsch W; Tlach L; Stambach D; Bauersfeld U Congenit Heart Dis; 2010; 5(3):278-84. PubMed ID: 20576047 [TBL] [Abstract][Full Text] [Related]
13. Atrial natriuretic peptide levels in rheumatic mitral regurgitation and response to angiotensin-converting enzyme inhibitors. Kula S; Tunaoglu FS; Olgunturk R; Gokcora N Can J Cardiol; 2003 Mar; 19(4):405-8. PubMed ID: 12704487 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333 [TBL] [Abstract][Full Text] [Related]
15. Functional mitral regurgitation and chronic heart failure. Ennezat PV; Marechaux S; Asseman P; Lejemtel TH; Van Belle E; Bauters C; De Groote P Minerva Cardioangiol; 2006 Dec; 54(6):725-33. PubMed ID: 17167384 [TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Agricola E; Ielasi A; Oppizzi M; Faggiano P; Ferri L; Calabrese A; Vizzardi E; Alfieri O; Margonato A Eur J Heart Fail; 2009 Jun; 11(6):581-7. PubMed ID: 19398488 [TBL] [Abstract][Full Text] [Related]
17. Heart failure treatment: Keeping up with best practices. Brink D J Fam Pract; 2018 Jan; 67(1):18-26. PubMed ID: 29309468 [TBL] [Abstract][Full Text] [Related]
18. ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. DeVore AD; Al-Khatib SM JACC Heart Fail; 2019 Oct; 7(10):907-910. PubMed ID: 31521688 [No Abstract] [Full Text] [Related]
19. MY APPROACH to treating heart failure with reduced ejection fraction. Greenberg BH Trends Cardiovasc Med; 2014 Nov; 24(8):367-8. PubMed ID: 25267506 [No Abstract] [Full Text] [Related]